Appl. No. 09/778,187

Docket No. 2873-US-NP

2. Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-19 (Canceled)

- 20. (Currently amended) An isolated polypeptide comprising an amino acid sequence that is at least 90% identical to amino acids X_1 to X_2 as shown in SEQ ID NO: 2 wherein X_1 is 1 or 39 and X_2 is 374 or 442, said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.
- 21. (Previously presented) The isolated polypeptide according to Claim 20, wherein X_2 is 374.
- 22. (Currently amended) An isolated polypeptide selected from the group consisting of:
 - (a) a polypeptide comprising amino acids X₁ to X₂ as shown in SEQ ID NO:
 2, wherein X₁ is 1 or 39 and X₂ is 374 or 442;
 - (b) a polypeptide comprising amino acids X_3 to X_4 as shown in SEQ ID NO: 4, wherein X_3 is 1 or 21 and X_4 is 356 or 423; and
 - (c) a polypeptide comprising a fragment of amino acids X₁ to X₂ in (a) or X₃ to X₄ in (b), wherein said fragment has 1 to 5 amino acids removed from either the amino or carboxy terminus of amino acids 39-374 of SEQ ID NO: 2 or amino acids 21-356 of SEQ ID NO: 4;

said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.

23. (Currently amended) The isolated polypeptide according to Claim 22 comprising amino acids X_1 to X_2 as shown in SEQ ID NO: 2 or a fragment of said amino acids, wherein X_1 is 1 or 39 and X_2 is 374 or 442, wherein said fragment has 1

Appl. No. 09/778,187

Docket No. 2873-US-NP

to 5 amino acids removed from either the amino or carboxy terminus of amino acids 39-374 of SEQ ID NO: 2.

- 24. (Previously presented) The isolated polypeptide according to Claim 23 wherein X₂ is 374.
- 25. (Previously presented) The isolated polypeptide according to Claim 23 wherein X₂ is 442.
- 26. (Currently amended) The isolated polypeptide according to Claim 22 comprising amino acids X₃ to X₄ as shown in SEQ ID NO: 4 or a fragment of said amino acids, wherein X₃ is 1 or 21 and X₄ is 356 or 423, wherein said fragment has 1 to 5 amino acids removed from either the amino or carboxy terminus of amino acids 21-356 of SEO ID NO: 4.
- 27. (Previously presented) The isolated polypeptide according to Claim 26 wherein X_4 is 356.
- 28. (Previously presented) The isolated polypeptide according to Claim 26 wherein X₄ is 423.
- 29. (Currently amended) The isolated polypeptide according to Claim <u>2324</u> or <u>2627</u> that is soluble.
- 30. (Currently amended) A fusion polypeptide comprising the polypeptide according to Claim <u>2220</u>.
- 31. (Previously presented) The fusion polypeptide according to Claim 30, wherein said fusion polypeptide comprises a Fc region, or a peptide linker, or a Fc region and a peptide liker.
- 32. (Currently amended) An oligomer comprising the polypeptide according to Claim 2220.

Appl. No. 09/778,187

Docket No. 2873-US-NP

- 33. (Previously presented) The oligomer according to Claim 32 which is a dimer, a trimer, or a tetramer.
- 34. (Currently amended) A composition comprising the polypeptide according to Claim 2220 and a suitable carrier.

35-63. (Cancelled)